- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05087251
The Transitions Project: Efficacy Trial
Randomized Trial of an Intervention to Enhance Quality of Life in Adults Completing Lung Cancer Treatment With Curative Intent
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a randomized controlled trial to test the efficacy of a brief psychoeducational intervention relative to a control condition for improving quality of life in patients with lung cancer who are transitioning from treatment to surveillance.
In this study, participants will complete survey questions and will be randomly assigned to receive a 5-session program or a 1-session program.
It is expected that about 100 people will take part in this research study.
The American Lung Association is supporting this research by providing funding for the research study.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lara Traeger, PhD
- Numéro de téléphone: (617) 643-4314
- E-mail: LTRAEGER@mgh.harvard.edu
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital Cancer Center
-
Contact:
- Lara Traeger, PhD
- Numéro de téléphone: 617-643-4314
- E-mail: LTRAEGER@mgh.harvard.edu
-
Chercheur principal:
- Lara Traeger, PhD
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute
-
Contact:
- Sharon Bober, PhD
- Numéro de téléphone: 617-632-6547
- E-mail: Sharon_Bober@DFCI.HARVARD.EDU
-
Chercheur principal:
- Timothy Sannes, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 21 or older
- Able to read and respond in English
- Diagnosis of non-small cell lung cancer or small cell lung cancer
- Documented curative treatment plan including systemic therapy +/- radiation and +/- surgery
Completed cancer treatment within past 3 weeks
- If final treatment is systemic therapy +/- radiation: within 3 weeks after cancer care team determination that treatment is complete
- If final treatment is surgery: within 3 weeks after hospital discharge following surgery
Exclusion Criteria:
- Comorbid health condition that would interfere with study participation
- Current participation in cognitive behavioral therapy treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Intervention: Five Psycho-educational Sessions
Approximately 6 weeks after the patient's cancer treatment is complete, participants in the intervention arm will proceed to receive up to 5 study sessions (approximately weekly, ~50 minutes each) with a trained interventionist focused on psychoeducational topics.
This arm was designed to enhance patient skills to address key concerns during the transition from treatment to surveillance, using a cognitive-behavioral approach.
Sessions will be based on an intervention manual.
|
5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
|
Expérimental: Enhanced Usual Care: One Psycho-educational Session
At approximately 6 weeks after treatment completion (as defined by our eligibility criteria), control patients will attend one study session (~50 minutes) with a study clinician.
This session is designed to control for patient access and connection to psychosocial resources as recommended in recent work.
|
1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Quality of life: Functional Assessment of Cancer Therapy-Lung Cancer
Délai: Up to 12 weeks
|
We will investigate longitudinal differences in quality of life between study groups (Functional Assessment of Cancer Therapy-Lung Cancer score range 0-144, with higher scores indicating better quality of life)
|
Up to 12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Fear of cancer recurrence: Fear of Cancer Recurrence Scale 7
Délai: Up to 12 weeks
|
We will investigate longitudinal differences in fear of cancer recurrence between study groups (Fear of Cancer Recurrence Scale 7, score range 7-35, with higher scores indicating more fear of cancer recurrence)
|
Up to 12 weeks
|
Symptom burden: Edmonton Symptom Assessment Scale
Délai: Up to 12 weeks
|
We will investigate longitudinal differences in symptom burden (Edmonton Symptom Assessment Scale score range 0-90, with higher scores indicating more symptom burden)
|
Up to 12 weeks
|
Psychological symptom burden: Hospital Anxiety and Depression Scale
Délai: Up to 12 weeks
|
We will investigate longitudinal differences in psychological symptom burden (Hospital Anxiety and Depression Scale score range 0-42 with higher scores indicating more psychological symptom burden)
|
Up to 12 weeks
|
Social support: Multidimensional Scale of Perceived Social Support
Délai: Up to 12 weeks
|
We will investigate longitudinal differencs in social support (Multidimensional Scale of Perceived Social Support score range 12-84, with higher scores indicating more social support)
|
Up to 12 weeks
|
Social isolaton: Campaign to End Loneliness Measurement Tool
Délai: Up to 12 weeks
|
We will investigate longitudinal differences in social isolation (Campaign to End Loneliness measurement tool score range 0-12 with higher scores indicating more social isolation)
|
Up to 12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Lara Traeger, PhD, Massachusetts General Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 21-426
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .